2020-07-01

Cadence Health Strengthens Management Team

Promotes Samantha Miller to co-CEO

article heroarticle hero

OAKLAND, Calif. – July 1, 2020 – Cadence Health, a mission-driven organization focused on women’s health products, today announced the promotion of Samantha Miller to co-CEO. Ms. Miller is a co-founder of the company and has served as chief operating officer. 

“From the founding of the company when she secured the rights to our birth control pill formulations, Samantha has served alongside me as an integral executive of Cadence, directing and executing strategies to advance our mission to bring the Pill over the counter,” said Nap Hosang, M.D., co-CEO of Cadence Health. “This promotion is well deserved and I look forward to our continued partnership in leading Cadence’s quest for excellence in Women’s Health.”

Samantha is a biopharmaceutical executive leader with decades of experience managing business development strategy in the pharmaceutical industry. She is skilled in pharma partnering, product and technology acquisitions, corporate financing, commercial planning, supply chain negotiations, and regulatory management. Samantha started her career as a scientist, and during her early training at P&G Pharmaceuticals found her passion for building new biopharmaceutical companies. A seasoned pharma entrepreneur, Samantha served as Chief Business Officer for pharma start-ups InCarda Therapeutics and Dance Biopharm and led business development for mid-market ventures Theravance, Nektar, and Onyx. Samantha holds a BS in Biochemistry & Cell Biology from the University of California, San Diego, an MS in Immunology and an MBA in Finance from the University of Rochester.

Appoints Dr. Simon Gilburt, Vice President, Clinical Research and Medical Affairs

In addition, Cadence announced the appointment of Simon Gilburt, Ph.D., to the newly created position of Vice President, Clinical Research and Medical Affairs. 

“As we enter the final regulatory stages of bringing the birth control pill over the counter, Simon will be instrumental in conducting our final study, the Actual Use Trial for Zena in addition to preparing for the FDA advisory committee meeting, and evaluating additional OTC products to augment our portfolio and expand our reach.”

Simon Gilburt, Ph.D., brings over 30 years of global experience in research and new product development across the pharmaceutical industry. His areas of expertise include scientific and clinical research, Rx-to-OTC switch, claims support and development, and new product development across multiple indication areas. Prior to joining Cadence, Simon was global R&D Head of Category for allergy and cough/cold at Bayer Healthcare and was recognized for using insight driven research to drive growth, lifecycle management and introduction of new product innovation. Previously, Simon cut his teeth in Biotech and then spent many years at GlaxoSmithKline where he gained significant medical affairs leadership experience across Rx and OTC arenas including pipeline development, Rx-to-OTC switch and growth of existing portfolio.

About Cadence Health

Cadence Health is knocking down the obstacles between women and the reproductive health options they want – starting with our effort to move the Pill OTC. We’re making safe, affordable options available to all women, without a prescription. Based in Oakland, California, Cadence is founded, led, and supported by a diverse team of internationally renowned reproductive health experts, world-class entrepreneurs, and champions of women. A public benefits company, Cadence is committed to transforming reproductive health for all women everywhere.

Additional Articles

2020-09-01

Cadence Health Completes Series C Financing to Advance Over-the-Counter Switch for an Oral Birth Control Pill

Read More
article clip

2020-07-01

Cadence Health Completes Pivotal Studies of Zena™ in Effort to Bring Approved Oral Birth Control Pill Over-the-Counter

Read More
article clip

2020-07-01

Cadence Health Strengthens Management Team

Read More
article clip